Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

SPRY ARS Pharmaceuticals Inc

13,34

0,77 (6,13%)

Zuletzt aktualisiert: 21:02:00

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/15/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Christian Nasser as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Justin Chakma

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

ARS Pharmaceuticals (NASDAQ:SPRY)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more ARS Pharmaceuticals Charts.

ARS Pharmaceuticals (NASDAQ:SPRY)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more ARS Pharmaceuticals Charts.

News ARS Pharmaceuticals Inc

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
Dienstag 21 Januar 2025 (7 Stunden vor) • GlobeNewswire Inc.

Form 8-K - Current report
Montag 13 Januar 2025 (1 Woche vor) • Edgar (US Regulatory)

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
Montag 13 Januar 2025 (1 Woche vor) • GlobeNewswire Inc.

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Montag 6 Januar 2025 (2 Wochen vor) • GlobeNewswire Inc.

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Donnerstag 19 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 19 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Mittwoch 18 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 14 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Freitag 13 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 12 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Donnerstag 12 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Donnerstag 12 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Weitere ARS Pharmaceuticals Inc News-Artikel

Bund Lg40 Eur 4,75

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen